1.42

2.07% -0.03

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $1.42, with a volume of 2.18M. It is down -2.07% in the last 24 hours and down -12.35% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Previous Close:

$1.45

Open:

$1.41

24h Volume:

2.18M

Relative Volume:

0.42

Market Cap:

$310.69M

Revenue:

$95,000

Net Income/Loss:

$-327.27M

P/E Ratio:

-0.6698

EPS:

-2.12

Net Cash Flow:

$-239.25M

1W Performance:

-0.70%

1M Performance:

-12.35%

6M Performance:

-49.29%

1Y Performance:

-59.08%

1-Day Range:

$1.39

$1.49

1-Week Range:

$1.375

$1.53

52-Week Range:

$1.23

$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

361

Twitter

@AllogeneTx

Next Earnings Date

2025-03-04

Latest SEC Filings

ALLO's Discussions on Twitter

Compare ALLO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLO Allogene Therapeutics Inc	1.42	310.69M	95,000	-327.27M	-239.25M	-2.12
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Aug-08-24	Resumed	Oppenheimer	Outperform
May-31-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025

Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025

Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025

Mar 14, 2025